The Cash Cow in 'Fertility' Medicine
By Pamela M Tsigdinos,
Healthcare in America
| 10. 23. 2016
On average, the cost of a basic IVF cycle in the U.S ranges from $12,000 — $15,000 yet three out of four times it fails
20 million fails. This is one stat not discussed at the latest American Society for Reproductive Medicine (ASRM) Scientific Congress and Expo. It’s also not posted on fertility clinic member websites nor shared on their social media feeds but it should be.
Last week thousands of physicians, nurses, scientists and lab technicians gathered in Salt Lake City joined by legions of pharmaceutical representatives, ‘fertility’ entrepreneurs and service providers in full on ‘sell mode.’
It’s been nearly 40 years since in vitro fertilization (IVF) became available. There has been explosive growth in the size and scope of clinics and profit taking but no commensurate improvement in IVF outcomes.
Here are five other facts that aren’t widely known but should be:
Fact #1: ‘Fertility’ is now a huge market. That’s right: a market. The global In-Vitro Fertilization (IVF) market size was valued at $9.6 billion in 2014. A more recent report by Grand View Research, Inc. projects the global ... see more
Related Articles
By Zaria Gorvett, BBC Future | 04.12.2021
He Jiankui seemed nervous.
At the time, he was an obscure researcher working at the Southern University of Science and Technology in Shenzhen, China. But he had been working on a top-secret project for the last two years – and he was...
By Katherine Plumhoff, Teen Vogue | 04.09.2021
"Editing or Eggs" by daithifortytwo is
licensed under CC BY-NC-SA 2.0
The first advertisement was slid under the door of Maggie’s* Ivy League dorm room. The quarter sheet of thin paper featured a woman’s silhouette, leaping with open arms over...
By Catherine Hsu, The Daily Californian | 04.01.2021
CRISPR genome editing technology, which was developed at UC Berkeley, has been approved for clinical trials to correct gene mutations responsible for sickle cell disease.
Sickle cell disease has been an “early target” for gene therapy because it is caused...
At least five separate studies involving human embryo research are raising fresh versions of old questions about science, ethics and regulation. On March 17, Nature published two peer-reviewed papers about generating in vitro, with slightly different methods, “blastoids” or “human blastocyst-like structures.” (One team, perhaps trying to be cute, called them “iBlastoids” but the Nature summary article sensibly eschews this.) One process involved developing from human embryonic stem cells, the other used cells reprogrammed from adult tissues. A few...
